An estimated 70 to 80 percent of patients with advanced or stage four breast cancer develop bone metastases. Bone metastases occurs when the disease progresses to a patient's bones. When cancer spreads to the bone, it can make the bones weaker resulting in skeletal complications like fractures.
Results of a new treatment option for the treatment of bone metastases in patients with advanced breast cancer was recently presented at the 2009 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas. The treatment, denosumab, is an investigational medicine developed by Amgen. It works differently from existing bone treatments by specifically targeting a protein called RANK Ligand, which plays an important role in the formation and breakdown of bone. Denosumab significantly reduced the risk of developing multiple skeletal related events by 23 percent versus Zometa(R) in advanced breast cancer patients
NEWS: Results Show Treatment Option for Bone Metastases In Patients with Advanced Breast Cancer Superior over Standard of Care
FORMAT: B-roll and Soundbites
ADDITIONAL RESOURCES: Video, contact information and more available at: http://multivu.prnewswire.com/broadcast/41387/press.html
VIDEO PROVIDED BY: Amgen Inc
Contact: FOR MORE INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313 EXT. 3
CONTACT: FOR TECHNICAL INFORMATION OR HARD COPY, PLEASE CALL: MultiVu
Media Relations, 1-800-653-5313 EXT. 3
Web site: http://www.amgen.com/
